platinum has been researched along with Adverse Drug Event in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (5.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (15.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 6 (30.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, KJ; Chang, JH; Chen, HY; Chu, CY; Hsu, YC; Huang, SH; Kuo, LN; Liu, EH; Wang, SY; Yu, MC | 1 |
| Cheng, M; Deng, A; Fan, R; Gou, J; Lin, R; Liu, Y; Luo, L; Qi, B; Sang, R; Wei, G; Yang, L; Zhang, S; Zhao, M | 1 |
| Hirai, T; Iwamoto, T; Ogura, T; Shiraishi, C | 1 |
| Asagi, A; Furukawa, M; Furuse, J; Hara, H; Hosokawa, A; Ikeda, M; Kojima, M; Kojima, Y; Mizuno, N; Murohisa, G; Ohkawa, S; Okusaka, T; Okuyama, H; Shioji, K; Yamanaka, T | 1 |
| Ahn, JS; Ahn, MJ; Godin, RE; Hollingsworth, SJ; Jung, HA; Kim, HJ; Lee, SH; Mortimer, PGS; Park, K; Park, S; Park, WY; Shim, J; Smith, SA; Sun, JM | 1 |
| Xia, D; Xu, X; Yang, W; Zhang, Y | 1 |
| Amiri-Kordestani, L; Banerjee, A; Beaver, JA; Blumenthal, GM; Charlab, R; Chen, XH; Dave, K; Dinin, J; Eradiri, O; Ghosh, S; Goldberg, KB; Horne, HN; Howie, LJ; Ibrahim, A; Ison, G; Janoria, KG; Kelly, SL; Kluetz, PG; Lee, EY; Li, F; Manheng, W; Palmby, TR; Pazdur, R; Philip, R; Pierce, WF; Pierre, V; Ramamoorthy, A; Song, P; Sridhara, R; Tang, S; Yu, J; Zhang, L | 1 |
| Chen, Y; Li, Q; Li, R; Ren, X; Xia, S; Xu, F | 1 |
| Cai, GY; Chen, XM; Duan, ZY; Li, JJ; Liu, JQ; Yin, P | 1 |
| Bai, CX; Chen, HY; Chen, YY; Gao, ZQ; Han, BH; Jin, L; Lu, DR; Peng, J; Qian, J; Wang, HJ; Wang, JC; Wu, WT; Yang, J; Yang, LX; Zhao, XY | 1 |
| Berton-Rigaud, D; Fabbro, M; Favier, L; Lesoin, A; Lortholary, A; Mari, V; Pujade-Lauraine, E; Ray-Coquard, I; Selle, F; Sevin, E | 1 |
| Di Palma, M; Guillot, A; Médioni, J; Spaeth, D; Théodore, C | 1 |
| Cruz, MR; Riera, R; Santos, FN | 1 |
| Chen, L; Chen, Y; Zhong, D | 1 |
| Kamura, T; Kuzuya, K; Noda, K; Ochiai, K; Sugiyama, T; Tamura, K; Ushijima, K | 1 |
| Chu, Z; Huang, R; Jiang, J; Liang, X; Zhan, Q; Zhou, X | 1 |
| Djinović, V; Grgurić-Sipka, S; Miljković, D; Momcilović, M; Mostarica Stojković, M; Sabo, T; Trajković, V | 1 |
| Boos, J; Deuster, D; Dinnesen, AG; Jaehde, U; Krefeld, B; Lanvers-Kaminsky, C; Pieck, AC; Seifert, E; Würthwein, G | 1 |
| Demertzis, MA; Kotsis, A; Kovala-Demertzi, D; Lakovidou, Z; Mioglou, E; Mourelatos, D; Papageorgiou, A; Yadav, PN | 1 |
| Fell, GS | 1 |
5 review(s) available for platinum and Adverse Drug Event
| Article | Year |
|---|---|
Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Etoposide; Female; Humans; Irinotecan; Male; Platinum; Proportional Hazards Models; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma | 2018 |
Impact of aging on the risk of platinum-related renal toxicity: A systematic review and meta-analysis.
Topics: Aged; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Humans; Kidney Diseases; Neoplasms; Platinum; Prognosis | 2018 |
Chemotherapy for Advanced Non-Small-Cell Lung Cancer in Elderly Patients.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Humans; Neoplasm Staging; Platinum; Randomized Controlled Trials as Topic | 2016 |
Comparing the adverse effects of platinum in combination with etoposide or irinotecan in previously untreated small-cell lung cancer patients with extensive disease: A network meta-analyses.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Irinotecan; Network Meta-Analysis; Platinum; Small Cell Lung Carcinoma | 2017 |
Toxic metal exposure during medication.
Topics: Aluminum; Drug Contamination; Drug-Related Side Effects and Adverse Reactions; Fluid Therapy; Humans; Iron; Lithium; Metals; Parenteral Nutrition, Total; Platinum; Preservatives, Pharmaceutical; Renal Dialysis; Trace Elements | 1979 |
5 trial(s) available for platinum and Adverse Drug Event
| Article | Year |
|---|---|
Analysis of Clinical Factors in Olaparib-related Anemia Using Adverse Drug Event Reporting Databases.
Topics: Anemia; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Piperazines; Platinum; United States | 2023 |
A Phase II Trial of Everolimus in Patients with Advanced Pancreatic Neuroendocrine Carcinoma Refractory or Intolerant to Platinum-Containing Chemotherapy (NECTOR Trial).
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Neuroendocrine; Drug-Related Side Effects and Adverse Reactions; Everolimus; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Pancreatic Neoplasms; Platinum; Progression-Free Survival; Prospective Studies | 2020 |
Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biomarkers, Tumor; Cyclin-Dependent Kinase Inhibitor p16; Drug-Related Side Effects and Adverse Reactions; Female; Gene Amplification; Humans; Male; Middle Aged; Morpholines; Neoplasm Recurrence, Local; Platinum; Progression-Free Survival; Proto-Oncogene Proteins c-myc; Pyrazoles; Pyrimidines; Pyrimidinones; Rapamycin-Insensitive Companion of mTOR Protein; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53 | 2020 |
A phase II study of lenalidomide in platinum-sensitive recurrent ovarian carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Fallopian Tube Neoplasms; Female; Humans; Lenalidomide; Membrane Proteins; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Platinum; Thalidomide | 2014 |
Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study.
Topics: Adult; Aged; Bridged-Ring Compounds; Camptothecin; Disease-Free Survival; Docetaxel; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Irinotecan; Japan; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Platinum; Taxoids | 2013 |
10 other study(ies) available for platinum and Adverse Drug Event
| Article | Year |
|---|---|
How platinum-induced nephrotoxicity occurs? Machine learning prediction in non-small cell lung cancer patients.
Topics: Carcinoma, Non-Small-Cell Lung; Drug-Related Side Effects and Adverse Reactions; Humans; Lung Neoplasms; Machine Learning; Platinum | 2022 |
Topics: B7-H1 Antigen; Cell Cycle Proteins; Cell Line, Tumor; Cytoplasm; Drug-Related Side Effects and Adverse Reactions; Humans; Immunotherapy; Neoplasms; Nuclear Proteins; Platinum; Prodrugs; Transcription Factors; Tumor Microenvironment | 2023 |
The Immunosuppression of Etoposide Deserves Attention in Chemoimmunotherapy.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Drug-Related Side Effects and Adverse Reactions; Etoposide; Humans; Immunosuppression Therapy; Lung Neoplasms; Platinum; Prognosis; Small Cell Lung Carcinoma; Survival Rate | 2021 |
FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy.
Topics: Aged; BRCA1 Protein; BRCA2 Protein; Clinical Trials as Topic; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Female; Germ-Line Mutation; Humans; Indazoles; Maintenance Chemotherapy; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Piperidines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Progression-Free Survival; Risk Assessment | 2018 |
XBP1 promoter polymorphism modulates platinum-based chemotherapy gastrointestinal toxicity for advanced non-small cell lung cancer patients.
Topics: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; China; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; Female; Gastrointestinal Tract; Genotype; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Platinum; Polymorphism, Genetic; Promoter Regions, Genetic; Regulatory Factor X Transcription Factors; Transcription Factors; X-Box Binding Protein 1 | 2013 |
Efficacy and safety of Vinflunine for advanced or metastatic urothelial carcinoma in routine practice based on the French multi-centre CURVE study.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma; Disease-Free Survival; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Platinum; Retrospective Studies; Urologic Neoplasms; Urothelium; Vinblastine | 2016 |
Paclitaxel plus platinum or gemcitabine plus platinum in first-line treatment of advanced non-small-cell lung cancer: results from 6 randomized controlled trials.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Deoxycytidine; Drug-Related Side Effects and Adverse Reactions; Gemcitabine; Humans; Neoplasm Staging; Paclitaxel; Platinum; Randomized Controlled Trials as Topic; Treatment Outcome | 2013 |
Novel ruthenium complex K2[Ru(dmgly)Cl4].2H2O is toxic to C6 astrocytoma cell line, but not to primary rat astrocytes.
Topics: Animals; Antineoplastic Agents; Astrocytes; Astrocytoma; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Drug-Related Side Effects and Adverse Reactions; Growth Inhibitors; Ligands; Nitric Oxide; Nitrites; Organometallic Compounds; Platinum; Rats; Ruthenium; Spectrophotometry; Spectrophotometry, Infrared; Time Factors; Tumor Cells, Cultured | 2004 |
Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
Topics: Adolescent; Antineoplastic Agents; Bone Neoplasms; Child; Child, Preschool; Cisplatin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Related Side Effects and Adverse Reactions; Female; Hearing Loss, Sensorineural; Humans; Infant; Infusions, Intravenous; Kidney Diseases; Male; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Osteosarcoma; Platinum; Prospective Studies | 2006 |
Platinum(II) and palladium(II) complexes with 2-acetylpyridine thiosemicarbazone: cytogenetic and antineoplastic effects.
Topics: Animals; Antineoplastic Agents; Drug Screening Assays, Antitumor; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Male; Mice; Mice, Inbred Strains; Organometallic Compounds; Organoplatinum Compounds; Palladium; Platinum; Sister Chromatid Exchange; Thiosemicarbazones | 2001 |